PT  - JOURNAL ARTICLE
AU  - Jiang, Xilin
AU  - Zhang, Martin Jinye
AU  - Zhang, Yidong
AU  - Durvasula, Arun
AU  - Inouye, Michael
AU  - Holmes, Chris
AU  - Price, Alkes L.
AU  - McVean, Gil
TI  - Age-dependent topic modelling of comorbidities in UK Biobank identifies disease subtypes with differential genetic risk
AID  - 10.1101/2022.10.23.22281420
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.10.23.22281420
4099  - http://medrxiv.org/content/early/2023/04/28/2022.10.23.22281420.short
4100  - http://medrxiv.org/content/early/2023/04/28/2022.10.23.22281420.full
AB  - The analysis of longitudinal data from electronic health records (EHR) has potential to improve clinical diagnoses and enable personalised medicine, motivating efforts to identify disease subtypes from age-dependent patient comorbidity information. Here, we introduce an age-dependent topic modelling (ATM) method that provides a low-rank representation of longitudinal records of hundreds of distinct diseases in large EHR data sets. The model learns, and assigns to each individual, topic weights for several disease topics, each of which reflects a set of diseases that tend to co-occur within individuals as a function of age. Simulations show that ATM attains high accuracy in distinguishing distinct age-dependent comorbidity profiles. We applied ATM to 282,957 UK Biobank samples, analysing 1,726,144 disease diagnoses spanning all 348 diseases with ≥1,000 independent occurrences in the Hospital Episode Statistics (HES) data, identifying 10 disease topics under the optimal model fit. Analysis of an independent cohort, All of Us, with 211,908 samples and 3,098,771 disease diagnoses spanning 233 of the 348 UK Biobank diseases produced highly concordant findings. In UK Biobank we identified 52 diseases with heterogeneous comorbidity profiles (≥500 occurrences assigned to each of ≥2 topics), including breast cancer, type 2 diabetes (T2D), hypertension, and hypercholesterolemia. For most of these diseases, topic assignments were highly age-dependent, suggesting differences in disease aetiology for early-onset vs. late-onset disease. We defined subtypes of the 52 heterogeneous diseases based on the topic assignments, and compared genetic risk across subtypes using polygenic risk scores (PRS). We identified 18 disease subtypes whose PRS differed significantly from other subtypes of the same disease, including a subtype of T2D characterised by cardiovascular comorbidities and a subtype of asthma characterised by dermatological comorbidities. We further identified specific variants underlying these differences such as a T2D-associated SNP in the HMGA2 locus that has a higher odds ratio in the top quartile of cardiovascular topic weight (1.18±0.02) compared to the bottom quartile (1.00±0.02) (P=3 × 10-7 for difference, FDR = 0.0002 < 0.1). In conclusion, ATM identifies disease subtypes with differential genome-wide and locus-specific genetic risk profiles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by Wellcome (BST00080- H503.01 to XJ, 100956/Z/13/Z to GM, https:// wellcome.org); the Li Ka Shing Foundation (to GM, https://www.lksf.org); NIH grants R01 HG006399, R01 MH101244, and R37 MH107649 (to ALP); The Alan Turing Institute (https://www.turing.ac.uk), Health Data Research UK (https://www.hdruk.ac.uk), the Medical Research Council UK (https://mrc.ukri.org), the Engineering and Physical Sciences Research Council (EPSRChttps://epsrc.ukri.org) through the Bayes4Health programme Grant EP/R018561/1, and AI for Science and Government UK Research and Innovation (UKRI, https://www.turing.ac.uk/ research/asg) (to CH); BHF Chair award CH/12/2/29428 (to XJ). This work was supported by core funding from the: British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge Centre of Research Excellence (RE/13/6/30180) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at Wellcome Centre Human Genetics and All of Us program.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript